- Vertex’s latest autoimmune TCE play involves $28M upfront to AbCelleraAbCellera’s T-cell engager platform has reeled in a second client this summer, with Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.Fierce Biotech · 5h ago↗ source
- GSK prepares for patent cliff with $2.5B cost-cutting planThe pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.